Clinical significance, detection, and medical treatment for peripheral arterial disease

Journal of Cardiopulmonary Rehabilitation

Volumn 22, Issue 2, 2002, Pages 73-79

  Greenland, Philip ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CILOSTAZOL; PENTOXIFYLLINE;

ADULT; AGED; ARTERY DISEASE; BRAIN BLOOD FLOW; CLINICAL FEATURE; CORONARY ARTERY BLOOD FLOW; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; INTERMITTENT CLAUDICATION; ISCHEMIA; MALE; MICROCIRCULATION; NON INVASIVE MEASUREMENT; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PREVALENCE; QUESTIONNAIRE; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE; VASCULAR ENDOTHELIUM;

EID: 0036489964     PISSN: 08839212     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008483-200203000-00003     Document Type: Review

References (39)

1. The demographics of claudication and the aging of the American population
2. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys
3. Management of peripheral arterial disease (PAD)
4. Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease
5. The prevalence of peripheral arterial disease in a defined population
6. The natural history of claudication: Risk to life and limb
7. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease
8. Claudication as an "orphan disease": Rationale and goals of drug therapy for peripheral arterial disease
9. Peripheral arterial disease in the elderly: The Rotterdam Study
10. The epidemiology of peripheral arterial disease: Importance of identifying the population at risk
11. Epidemiology of peripheral arterial disease
12. Intermittent claudication: A condition with underrated risks
13. Palpation of peripheral pulses: A difficult art
14. Diabetes, intermittent claudication, and risk of cardiovascular events: The Framingham Study
15. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study
16. Update on some epidemiologic features of intermittent claudication: The Framingham Study
17. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease
18. Fibrinogen and peripheral arterial disease
19. The clinical relevance of the flow properties of blood cells
20. Risk factors and cardiovascular diseases associated with asymptomatic peripheral arterial occlusive disease. The Limburg PAOD study: Peripheral arterial occlusive disease
21. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population
22. The correlation between symptoms and non-invasive test results in patients referred for peripheral arterial disease testing
23. The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease: Results from noninvasive testing in a defined population
24. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study
25. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study
26. Management of intermittent claudication with pentoxifylline: Meta-analysis of randomized controlled trials
27. Conservative management of intermittent claudication
28. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial
29. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease
30. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial
31. Cilostazol
32. Effect of cilostazol, a phosdiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery
33. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells
34. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty
35. A comparison of cilostazol and pentoxifylline for treating intermittent claudication
36. Edinburgh Artery Study: Prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population
37. Atypical presentations of neurological illness in the elderly
38. Evaluating chest pain: The patient's presentation style alters the physician's diagnostic approach
39. Cost-effectiveness of diagnostic strategies for patients with chest pain